51 results about "Cardioplegias" patented technology

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and / or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and / or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

A disposable cartridge for use in extracorporeal blood perfusions systems that have a control unit for controlling the flow of fluids. The cartridge has a housing defining a plurality of internal passageways that connect to a cardiopulmonary circuit, a cardioplegia circuit and a suction circuit. The cartridge may be fitted with one or more of a bubble trap, a filter, and a valve.

The present invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's core body temperature, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ophthalmic condition, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereofwhereinA is —CH2OHB and C are —OH:D isA and B are trans with respect to each other:B and C are cis with respect to each other:C and D are cis or trans with respect to each other:R1 is —H, -halo, —CN, —N(R2)2, —OR2, —SR2, —NHC(O)R2, —NHC(O)N(R2)2, —NHC(O)OR2, —C(O)OR2, —C(O)R2, —C(O)N(R2)2, —OC(O)N(R2)2, —C(halo)3, or —NO2;each R2 is independently —H, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —(CH2)n-aryl, —(CH2)n-(3- to 7-membered monocyclic heterocycle, —(CH2)n-(8- to 12-membered bicyclic heterocycle), —(CH2)n—(C3-C8 monocyclic cycloalkyl), —(CH2)n—(C3-C8 monocyclic cycloalkenyl), —(CH2)n—(C8-C12 bicyclic cycloalkyl), or —(CH2)n—(C8-C12 bicyclic cycloalkenyl);each n is an integer ranging from 0 to 6;each p is an integer ranging from 1 to 6; andeach q is an integer ranging from 1 to 6.

Cardioplegia is delivered to a heart vessel by conducting the cardioplegia through an infusion lumen of a cannula. The cardioplegia communicates with a balloon disposed on a distal end of the cannula to cause the cardioplegia to inflate the balloon into sealing contact with a wall of the coronary sinus. The flow of cardioplegia is halted while preventing drainage of cardioplegia from the balloon, to maintain the balloon in its inflated state until such time as the flow of cardioplegia is resumed. Drainage of cardioplegia from the balloon is prevented by causing a valve to be shifted to a closed position blocking communication between the infusion lumen and the balloon. The valve can be shifted manually, or automatically in response to the halting of the delivery of cardioplegia.

A method for closed-chest cardiac surgical intervention relies on viewing the cardiac region through a thoracoscope or other viewing scope and endovascularly partitioning the patient's arterial system at a location within the ascending aorta. The cardiopulmonary bypass and cardioplegia can be induced, and a variety of surgical procedures performed on the stopped heart using percutaneously introduced tools. The method of the present invention will be particularly suitable for forming coronary artery bypass grafts, where an arterial blood source is created using least invasive surgical techniques, and the arterial source is connected to a target location within a coronary artery while the patient is under cardiopulmonary bypass and cardioplegia.

A single, multichannel catheter for extracorporeal circulation of blood to a patient undergoing cardiac treatments or surgery. The catheter has three independent channels and an expandable balloon. The first channel is the largest and delivers blood to a patient to maintain the patient's metabolism and perfusion throughout the treatment or surgery. A second, smaller channel is integrated into the wall of the first channel and delivers a biologically active fluid (e.g., for cardioplegia) to the heart and / or venting the left heart. A third, smaller channel is integrated into the wall of the first channel, and delivers an expansion fluid to the balloon to occlude the flow of blood to the heart. Preferably, the first channel accounts for at least about 70% of the total channel volume. The multichannel catheter is best prepared using an extrusion molding technique.